See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial

The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc’s KURA cancer drugs following a patient’s death in a clinical trial.

  • Kura reported that the Phase 1b study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probe the death.
  • Patients already on the drug can continue taking it.
  • According to Kura, the death was “potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.”
  • Until the partial clinical hold is resolved, Kura is suspending guidance on completing enrollment in the KOMET-001 Phase 1b study and determining the recommended Phase 2 dose of KO-539.
  • Earlier, the Company expected to complete enrollment in Q1 of 2022.
  • The oral drug is designed to block the interaction of two proteins - menin and KMT2A/MLL. 
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: KURA shares fell 16.9% at $13.81 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareSmall CapFDAMoversTrading IdeasGeneralacute myeloid leukemiaBriefsPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!